Propanc Biopharma, Inc.

PPCB Nasdaq SEC CIK 1517681
Follow Propanc Biopharma Weekly email: filings, results, news

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$6.4M +88.2% vs same quarter last year
EPS, diluted −$7.09 +97.7% vs same quarter last year
Operating cash flow −$1.1M −1087.6% vs same quarter last year
Operating income −$6.4M +88% vs same quarter last year
Net income by quarter
−$358.6K
−$354.3K
−$430.2K
−$54.1M
−$4.1M
−$4.8M
−$3.1M
−$6.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$58.9M
FY24−$1.8M
FY23−$2.7M
FY22−$2.7M
FY21−$2M
FY20−$4.7M
FY19−$5.8M
FY18−$7M
FY17−$7.9M
FY16−$9.4M
FY15−$3.4M
FY14−$829.6K
FY13−$1.4M
FY12−$11.4M
FY11−$2.2M
Free cash flowOperating cash flow minus capital expenditure
−$6M−$4M−$2M$0$2MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$2.1M
FY18-
FY17-
FY16−$4.5M
FY15−$1.4M
FY14$226.4K
FY13-
FY12-
FY11−$1.4M

News

No stories filed under Propanc Biopharma yet - coverage appears here as the news feed clusters it.